Vernalis plc (LON:VER) announced its quarterly earnings data on Tuesday. The company reported GBX (4.10) (($0.05)) earnings per share (EPS) for the quarter, topping the consensus estimate of GBX (4.50) (($0.06)) by GBX 0.40 ($0.01), Digital Look Earnings reports. Vernalis plc had a negative return on equity of 22.58% and a negative net margin of 198.87%. The company had revenue of GBX 207.90 billion for the quarter.

Vernalis plc (VER) traded up 0.000% during mid-day trading on Thursday, reaching GBX 15.625. The company’s stock had a trading volume of 27,100 shares. The company’s 50-day moving average price is GBX 16.74 and its 200 day moving average price is GBX 19.62. The firm’s market capitalization is GBX 82.24 million. Vernalis plc has a 52 week low of GBX 15.00 and a 52 week high of GBX 45.13.

COPYRIGHT VIOLATION NOTICE: This story was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at

VER has been the subject of a number of analyst reports. N+1 Singer restated a “hold” rating and set a GBX 28 ($0.36) target price on shares of Vernalis plc in a report on Monday, August 7th. RX Securities restated a “buy” rating on shares of Vernalis plc in a report on Monday, August 7th. Stifel Nicolaus lowered their target price on Vernalis plc from GBX 24 ($0.31) to GBX 21 ($0.27) and set a “hold” rating for the company in a report on Monday, August 7th. Finally, Panmure Gordon restated a “hold” rating and set a GBX 31 ($0.40) target price on shares of Vernalis plc in a report on Monday, August 7th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Vernalis plc currently has a consensus rating of “Hold” and a consensus target price of GBX 39.40 ($0.51).

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with's FREE daily email newsletter.